Brief: GT Biopharma To Present Updated Positive Safety Data From GTB-3550 Monotherapy TriKE™ Trial At ESMO Congress 2021
15/09/2021 12:17
Sept 15 (Reuters) - GT Biopharma Inc GTBP.O :
* GT BIOPHARMA ANNOUNCES UPDATED POSITIVE SAFETY DATA FROM
PHASE 1
GTB-3550 MONOTHERAPY TRIKE™ TRIAL AN INVESTIGATIONAL
IMMUNOTHERAPY FOR REFRACTORY CANCERS TO BE PRESENTED AT ESMO
CONGRESS 2021
Source text for Eikon: ID:nPn4CWNj1a
Further company coverage: GTBP.O
((Reuters.Briefs@thomsonreuters.com;))